Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10102-10115

  Li, Xiaolei ^a,b   Tao, Junyan ^b,c   Cigliano, Antonio ^d   Sini, Marcella ^d   Calderaro, Julien ^e,f   Azoulay, Daniel ^e   Wang, Chunmei ^b   Liu, Yan ^a   Jiang, Lijie ^b   Evert, Katja ^d   Demartis, Maria I ^g   Ribback, Silvia ^d   Utpatel, Kirsten ^d   Dombrowski, Frank ^d   Evert, Matthias ^d   Calvisi, Diego F ^d,g   Chen, Xin ^b,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e HENRI MONDOR HOSPITAL   (France)

^f INSERM   (France)

^g UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cholangiocarcinoma; HCC; Hippo; Liver tumor; PI3K

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR YAP1; PHOSPHOPROTEIN; PIK3CA PROTEIN, HUMAN; PIK3CA PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP PROTEIN, MOUSE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CELL GROWTH; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HEPATOCELLULAR CARCINOMA CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; CELL PROLIFERATION; EXPERIMENTAL LIVER NEOPLASM; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION;

EID: 84929598281     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3546     Document Type: Article

References (44)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015.
2. Rizvi S and Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145: 1215-1229.
3. Bosch FX, Ribes J, Diaz M and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1): S5-S16.
4. Mo JS, Park HW and Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014; 15: 642-656.
5. Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010; 19: 491-505.
6. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21: 2747-2761.
7. Steinhardt AA, Gayyed MF, Klein AP, Dong JX, Maitra A, Pan D, Montgomery EA and Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008; 39: 1582-1589.
8. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125: 1253-1267.
9. Xu MZ, Yao TJ, Lee NPY, Ng IOL, Chan YT, Zender L, Lowe SW, Poon RTP and Luk JM. Yes-Associated Protein Is an Independent Prognostic Marker in Hepatocellular Carcinoma. Cancer-Am Cancer Soc. 2009; 115: 4576-4585.
10. Fruman DA and Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13: 140-156.
11. Porta C, Paglino C and Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4:64.
12. Matter MS, Decaens T, Andersen JB and Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma:current state and future trends. Journal of hepatology. 2014; 60: 855-865.
13. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008; 135: 1972-1983.
14. Polivka J and Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Therapeut. 2014; 142: 164-175.
15. Chiarini F, Evangelisti C, McCubrey JA and Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci. 2014.
16. Manning BD and Cantley LC. AKT/PKB signaling:Navigating downstream. Cell. 2007; 129: 1261-1274.
17. Samuels Y, Wang ZH, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell DM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554.
18. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH and Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008; 15: 1064-1069.
19. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005; 24: 1477-1480.
20. Miyaki M, Lijima T, Yamaguchi T, Takahashi K, Matsmnoto H, Yasutome M, Funata N and Mori T. Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer. 2007; 121: 1627-1630.
21. Strassburger K, Tiebe M, Pinna F, Breuhahn K and Teleman AA. Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. Developmental biology. 2012; 367: 187-196.
22. Tao JY, Calvisi DF, Ranganathan S, Cigliano A, Zhou LL, Singh S, Jiang LJ, Fan BA, Terracciano L, Armeanu-Ebinger S, Ribback S, Dombrowski F, Evert M, et al. Activation of beta-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. Gastroenterology. 2014; 147: 690-701.
23. Calvisi DF, Wang CM, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, et al. Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma. Gastroenterology. 2011; 140: 1071-U1542.
24. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, et al. Yes-Associated Protein Upregulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology. 2013; 144: 1530-U1368.
25. Zhao B, Ye X, Yu JD, Li L, Li WQ, Li SM, Yu JJ, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC and Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22: 1962-1971.
26. Zhao B, Li L, Lei QY and Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Gene Dev. 2010; 24: 862-874.
27. Zheng Z, Amran SI, Thompson PE and Jennings IG. Isoform-selective inhibition of phosphoinositide 3-kinase:identification of a new region of nonconserved amino acids critical for p110alpha inhibition. Mol Pharmacol. 2011; 80:657-664.
28. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26: 1300-1305.
29. Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S and Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of hepatology. 2014; 61: 1088-1096.
30. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X and Willenbring H. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122: 2911-2915.
31. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH and Verma IM. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012; 338: 1080-1084.
32. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, Rupec RA, Gerhard M, Schmid R, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013; 152: 25-38.
33. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 2014; 513: 110-114.
34. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell. 2014; 158: 579-592.
35. Kitade M, Factor VM, Andersen JB, Tomokuni A, Kaji K, Akita H, Holczbauer A, Seo D, Marquardt JU, Conner EA, Lee SB, Lee YH and Thorgeirsson SS. Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Gene Dev. 2013; 27: 1706-1717.
36. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ and Camargo FD. Hippo pathway activity influences liver cell fate. Cell. 2014; 157: 1324-1338.
37. Huntzicker EG, Hotzel K, Choy L, Che L, Ross J, Pau G, Sharma N, Siebel CW, Chen X and French DM. Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology. 2014.
38. Mazur PK, Riener MO, Jochum W, Kristiansen G, Weber A, Schmid RM and Siveke JT. Expression and Clinicopathological Significance of Notch Signaling and Cell-Fate Genes in Biliary Tract Cancer. Am J Gastroenterol. 2012; 107: 126-132.
39. Andersson ER and Lendahl U. Therapeutic modulation of Notch signalling--are we there yet? Nat Rev Drug Discov. 2014; 13: 357-378.
40. Espinoza I and Miele L. Notch inhibitors for cancer treatment. Pharmacol Therapeut. 2013; 139: 95-110.
41. Chen X and Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014; 184: 912-923.
42. Frith CH, Ward JM and Turusov VS. Tumours of the liver. IARC scientific publications. 1994; 111: 223-269.
43. Delogu S, Wang C, Cigliano A, Utpatel K, Sini M, Longerich T, Waldburger N, Breuhahn K, Jiang L, Ribback S, Dombrowski F, Evert M, Chen X, et al. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget. 2014.
44. Allen RA and Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949; 25: 647-655.